DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
India in the Changing Landscape of Life-Sciences Research & Development
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Subscribe To Our Newsletter & Stay Updated